The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Results of the EuroNet-PHL-C1 trial: omission of radiotherapy in children and adolescents with cHL
Christine Mauz-Körholz, MD, Justus-Liebig University, Giessen, Germany, presents the findings of the EuroNet-PHL-C1 trial (NCT00433459), which investigated response-adapted omission of radiotherapy and compared consolidation chemotherapy regimens in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (cHL). The results showed that in patients who adequately respond to treatment, radiotherapy can be omitted, reducing the likelihood of future malignancies, such as breast cancer. Additionally, dacarbazine in consolidation was found to be less gonadotoxic than procarbazine, allowing for improved fertility preservation. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
